THE CORPORATE REPUTATION OF THE PHARMA INDUSTRY IN 2015: THE PERSPECTIVE OF 58 LATIN AMERICAN PATIENT GROUPS (1st edition)

Report published by PatientView, June 2016

 

If you would like more information, or would like to get hold of this report, please use contact details below

 
  • Contact: Alex Wyke

  • Tel: +44-(0)1547-520-965

  • Email: report@patient-view.com

  • Website: http://www.patient-view.com

  • Publication date: 
  • Friday,  17th June 2016
 

About this report

London, Friday, 17th June 2016. This report is based on the findings of a PatientView November 2015-January 2016 survey exploring the views of 58 Latin American patient groupsfrom Argentina, Brazil, Chile, Colombia, Guatemala, Mexico, Nicaragua, Paraguay, Peru, Puerto Rico, and Venezuela.

The report provides feedback (from the perspective of  these patient groups) on the corporate reputation of the pharma industry during 2015, as well as on the performance of 13 pharma companies trading in Latin America at six key indicators that influence corporate reputation. Results are compared with those of other countries/geographic regions from the 2015 survey.

For the purposes of this report, the phrase ‘corporate reputation’ is defined as the extent to which pharma companies are meeting the expectations of patients and patient groups.

 
 
 
 

The six indicators of corporate reputation:

  1. Patient centricity.
  2. Patient information.
  3. Patient safety.
  4. Useful products.
  5. Transparency.  And ...
  6. Integrity.

The 13 companies analysed:

AbbVie I AstraZeneca I Bayer I Boehringer Ingelheim I Bristol-Myers Squibb I GSK I Janssen I Lilly I Merck & Co I Novartis I Pfizer I Roche I Sanofi

 

“Los medicamentos son muy caros, estamos siempre buscando la manera en que nuestro grupo de beneficiarios puedan tener acceso al tratamiento, sin interrupción.”

—Regional Mexico-based patient group specialising in chronic disease in general

“Existe contacto con médicos pero no hay programas para los pacientes.”

—National Columbia-based patient group specialising in epilepsy

 

INDUSTRY-WIDE FINDINGS

The 58 patient groups based in Latin America and responding to the 2015 ‘Corporate Reputation of Pharma’ survey were significantly more positive about the pharma industry’s corporate reputation than patient groups from other parts of the world in 2015 (with the possible exception of patient groups from Eastern Europe).

  • 61.8% of the 58 patient groups based in Latin America that responded to the 2015 ‘Corporate Reputation of Pharma’ survey stated that the pharma industry as a whole had an “Excellent” or “Good” corporate reputation that year. The equivalent figure for patient groups from all parts of the world in 2015 was 44.7%.
  • Patient groups based in Latin America responding in 2015 ranked the pharma industry 1st out of 8 healthcare-industry sectors for corporate reputation—ahead of biotech, private healthcare, medical devices, generics, not-for-profit health insurers, retail pharmacists, and for-profit health insurers. Pharma ranked 5th in the global results for 2015.
 
 

In 2015, the pharma industry received positive responses from the 58 respondent Latam patient groups for several of its key activities (more positive than from patient groups in most other countries and regions of the world).  Results include:

  • As many as 85% of the patient groups based in Latin America responding to the 2015 ‘Corporate Reputation of Pharma’ survey described the industry as a whole as “Excellent” or “Good” at innovation—a far-higher figure than from patient groups of any other geographic area (again, bar Eastern Europe). The equivalent 2015 figure from patient groups worldwide was 69%.
  • 48% of the patient groups based in Latin America responding to the 2015 ‘Corporate Reputation of Pharma’ survey described the industry as a whole as “Excellent” or “Good” at being transparent in all corporate activities—a much-higher figure than from patient groups of any other geographic area. The equivalent figure from patient groups worldwide in 2015 was 26%.
  • As many as 37% of the patient groups based in Latin America responding to the 2015 ‘Corporate Reputation of Pharma’ survey described the industry as a whole as “Excellent” or “Good” at providing patients with services outside the usual business remit—once more, a higher figure than from patient groups of any other geographic area. The equivalent figure from patient groups worldwide in 2015 was 26%.
 
 

HOWEVER, PATIENT GROUPS IN LATIN AMERICA DO BELIEVE THAT PHARMA NEEDS TO IMPROVE IN SOME SUBJECT AREAS ...

When asked by the ‘Corporate-Reputation’ survey in 2015 to identify the single most-important single policy a pharma company can adopt to improve its corporate reputation, Latam patient groups nominated: having a fair pricing policy.

     

    HOW INDIVIDUAL PHARMA COMPANIES PERFORMED FOR CORPORATE REPUTATION IN LATIN AMERICA IN 2015

     

    The table shows the 13 pharma companies ranked according to their corporate reputation, as measured by Latam patient groups in 2015, versus the same companies' overall rankings among patient groups worldwide in 2015 (the latter a ranking out of 48 companies).

    • Not only did Latin American patient groups nominate Novartis overall 1st for corporate reputation among the 13 companies in 2015, they also ranked the company 1st for all six individual PatientView indicators of corporate reputation that year. Novartis owed its strong performance in Latin America in 2015 to positive feedback from two types of Latam patient groups: Brazilian patient groups, and neurological patient groups from across Latin America.
     
     

    END OF STATEMENT

    PatientView is a UK-based research organisation that consults closely with patient groups, and publicises the work of the patient-advocacy movement.